GlassScriptPhysician profile
Kori Ascher
NPI 1083019749
$49,870.01
in general payments reported to CMS, 2019-2025
10 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $186 · 2021: $279 · 2022: $603 · 2023: $18K · 2024: $17K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Consulting Fee: $18K · Food and Beverage: $3,723 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,174 · Travel and Lodging: $1,406 · Education: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,692.00 |
| Consulting Fee | $18,427.50 |
| Food and Beverage | $3,722.61 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,174.00 |
| Travel and Lodging | $1,406.14 |
| Education | $379.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $43,348.04 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $5,673.67 | 2020-2025 | |
| Inspire Medical Systems, INC. | $248.84 | 2023-2024 | Inspire |
| Axsome Therapeutics, INC. | $232.00 | 2022-2024 | Sunosi |
| Fisher & Paykel Healthcare INC | $106.46 | 2024-2025 | Fisher & Paykel Healthcare |
| Resmed Corp | $90.20 | 2022-2023 | |
| Avadel Cns Pharmaceuticals, LLC | $79.07 | 2024 | Lumryz |
| Ambu INC. | $38.35 | 2020 | |
| Lilly USA, LLC | $32.42 | 2025 | Zepbound |
| Idorsia Pharmaceuticals US INC | $20.96 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kori Ascher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.